ADC Therapeutics SA Return on Tangible Equity 2019-2022 | ADCT
Current and historical return on tangible equity values for ADC Therapeutics SA (ADCT) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| ADC Therapeutics SA Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2022-12-31 |
$-0.16B |
$0.07B |
-150.72% |
| 2022-09-30 |
$-0.17B |
$0.09B |
-134.69% |
| 2022-06-30 |
$-0.19B |
$0.10B |
-129.64% |
| 2022-03-31 |
$-0.20B |
$0.15B |
-110.73% |
| 2021-12-31 |
$-0.23B |
$0.15B |
-109.09% |
| 2021-09-30 |
$-0.25B |
$0.17B |
-99.31% |
| 2021-06-30 |
$-0.20B |
$0.23B |
-66.39% |
| 2021-03-31 |
$-0.26B |
$0.29B |
-87.48% |
| 2020-12-31 |
$-0.25B |
$0.33B |
-112.07% |
| 2020-06-30 |
$-0.20B |
$0.19B |
-429.95% |
| 2020-03-31 |
$-0.10B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.152B |
$0.210B |
|
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
|
